Netspend and Rêv Combine Global Portfolio Under Parent Brand Name Ouro
Netspend and Rêv Worldwide announced today they have completed the integration of their key strategic assets and formed a new global financial services, loyalty and technology solutions parent company named Ouro. The new company plans to aggressively expand its multi-brand portfolio spanning prepaid, debit, cross-border payments, and loyalty products and service innovations across the globe. The new name and strategy follow the May return of the founders to run the company they started nearly 25 years ago.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231101117696/en/
Roy Sosa, Co-founder, CEO and Chairman of Ouro (Photo: Business Wire)
The new Ouro global group of fintech brands will maintain Netspend as a flagship brand and leader in the prepaid card market, serving underserved customers looking to access payment network merchant acceptance. The company’s X World Wallet, which was developed by Rêv, will continue to expand domestically and internationally with a focus on lifestyle, tourism and cross-border commerce.
“With the successful integration and alignment of our people, platforms, and purpose, we are primed to help more consumers worldwide access innovative financial solutions that provide exceptional value, control, flexibility and security,” said Ouro Co-founder, Chairman and CEO Roy Sosa. “The decision to rebrand as Ouro signifies the transformation we’ve undergone the past six months and reignites our shared commitment to our legacy of customer and partner-centric innovation and reminds us of the infinite possibilities that come with pursuing it.”
The name Ouro draws inspiration and meaning from the Greek word “ouroboros,” an ancient symbol depicting a closed circle with a dragon consuming its own tail. Manifesting across diverse cultures and contexts throughout history, the symbol evokes continuous reinvention, renewal, the unity of beginnings and endings, the cyclical nature of our journeys and endless possibility.
The Ouro brand acknowledges and reflects the cyclical nature of the journey and transformation the company has undergone since founders Roy and Bertrand Sosa returned to the helm with an acquisition completed in May.
“While we take pride in the role Netspend has played in the financial empowerment ecosystem pioneering prepaid, debit and mobile payment solutions, billions more consumers can benefit from these essential products and services, and we remain committed to reaching them,” Ouro Co-Founder, President and Chief Brand Officer Bertrand Sosa noted. “Ouro is building on a vast set of strategic assets – including several proprietary payment processing platforms, a worldwide network of card sale and cash load retail partners, and multiple innovative international brands which today span the entire economic ladder and a global footprint.”
Ouro will capitalize on its existing portfolio of consumer brands, including one of the largest prepaid debit card providers in the United States under the Netspend brand, as well as international brand X World Wallet direct-to-consumer program, Walletplus in partnership with Etihad Airways, and Global Wallet in partnership with Itaú bank in Brazil, among other consumer and enterprise programs under management. With the Rêv brand, Ouro will continue to develop and expand its growing suite of tailored enterprise solutions. The company also has strategic partnerships in the sports and entertainment world, including blue-chip properties across NASCAR, MLB, MLS, NBA, with other properties soon to be announced, adding to product co-brand strategies and opportunities.
About Ouro
Ouro is a global, vertically-integrated financial services and technology company dedicated to the delivery of innovative financial empowerment solutions to consumers worldwide. Ouro’s financial products and services span prepaid, debit, cross-border payments, and loyalty solutions for consumers and enterprise partners. Since its founding in 1999 by industry pioneers Roy and Bertrand Sosa, Ouro products have processed almost a trillion dollars in transaction volume and served millions of customers worldwide. The company is headquartered in Austin, Texas with regional offices across the world. For more information, visit www.ouro.global.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231101117696/en/
Contact information
Meredith DeSpain
mdespain@legendlabs.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom